Bank of America
RARE icon

Bank of America’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bank of America’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9M Sell
1,046,546
-167,382
-14% -$3.77M ﹤0.01% 2305
2025
Q4 		$27.9M Buy
1,213,928
+558,907
+85% +$18.4M ﹤0.01% 2008
2025
Q3 		$19.7M Buy
655,021
+17,331
+3% +$520K ﹤0.01% 2639
2025
Q2 		$23.2M Buy
637,690
+109,710
+21% +$3.96M ﹤0.01% 2411
2025
Q1 		$19.1M Buy
527,980
+139,478
+36% +$5.8M ﹤0.01% 2484
2024
Q4 		$16.3M Sell
388,502
-537,408
-58% -$26.7M ﹤0.01% 2490
2024
Q3 		$51.4M Buy
925,910
+378,092
+69% +$19.3M ﹤0.01% 1540
2024
Q2 		$22.5M Buy
547,818
+117,282
+27% +$5.01M ﹤0.01% 2124
2024
Q1 		$20.1M Buy
430,536
+87,124
+25% +$4.11M ﹤0.01% 2276
2023
Q4 		$16.4M Sell
343,412
-31,325
-8% -$1.21M ﹤0.01% 2366
2023
Q3 		$13.4M Buy
374,737
+15,871
+4% +$629K ﹤0.01% 2432
2023
Q2 		$16.6M Sell
358,866
-112,084
-24% -$5.2M ﹤0.01% 2204
2023
Q1 		$18.9M Buy
470,950
+78,556
+20% +$3.37M ﹤0.01% 2180
2022
Q4 		$18.2M Buy
392,394
+25,198
+7% +$991K ﹤0.01% 2104
2022
Q3 		$15.2M Sell
367,196
-46,535
-11% -$2.39M ﹤0.01% 2197
2022
Q2 		$24.7M Buy
413,731
+78,248
+23% +$4.82M ﹤0.01% 1825
2022
Q1 		$24.4M Buy
335,483
+88,687
+36% +$6.17M ﹤0.01% 1960
2021
Q4 		$20.8M Sell
246,796
-18,077
-7% -$1.47M ﹤0.01% 2175
2021
Q3 		$23.9M Buy
264,873
+28,365
+12% +$2.56M ﹤0.01% 2014
2021
Q2 		$22.6M Sell
236,508
-42,793
-15% -$4.46M ﹤0.01% 2031
2021
Q1 		$31.8M Sell
279,301
-9,012
-3% -$1.23M ﹤0.01% 1638
2020
Q4 		$39.9M Buy
288,313
+18,795
+7% +$2.23M 0.01% 1334
2020
Q3 		$22.2M Buy
269,518
+67,613
+33% +$5.6M ﹤0.01% 1613
2020
Q2 		$15.8M Sell
201,905
-39,107
-16% -$2.59M ﹤0.01% 1811
2020
Q1 		$10.7M Buy
241,012
+86,631
+56% +$4.5M ﹤0.01% 2010
2019
Q4 		$6.59M Buy
154,381
+15,559
+11% +$642K ﹤0.01% 2974
2019
Q3 		$5.94M Sell
138,822
-21,545
-13% -$1.17M ﹤0.01% 3034
2019
Q2 		$10.2M Buy
160,367
+30,903
+24% +$1.97M ﹤0.01% 2538
2019
Q1 		$8.98M Buy
129,464
+68,520
+112% +$3.91M ﹤0.01% 2586
2018
Q4 		$2.65M Buy
60,944
+10,365
+20% +$566K ﹤0.01% 3606
2018
Q3 		$3.86M Sell
50,579
-15,212
-23% -$1.24M ﹤0.01% 3442
2018
Q2 		$5.06M Buy
65,791
+25,219
+62% +$1.63M ﹤0.01% 3144
2018
Q1 		$2.07M Buy
40,572
+6,967
+21% +$351K ﹤0.01% 3860
2017
Q4 		$1.56M Sell
33,605
-36,168
-52% -$1.77M ﹤0.01% 4161
2017
Q3 		$3.72M Buy
69,773
+25,749
+58% +$1.53M ﹤0.01% 3449
2017
Q2 		$2.73M Sell
44,024
-4,853
-10% -$292K ﹤0.01% 3613
2017
Q1 		$3.31M Buy
48,877
+4,417
+10% +$337K ﹤0.01% 3417
2016
Q4 		$3.13M Buy
44,460
+4,377
+11% +$311K ﹤0.01% 3375
2016
Q3 		$2.84M Buy
40,083
+3,128
+8% +$200K ﹤0.01% 3347
2016
Q2 		$1.81M Buy
36,955
+7,894
+27% +$511K ﹤0.01% 3710
2016
Q1 		$1.84M Sell
29,061
-16,499
-36% -$1.08M ﹤0.01% 3639
2015
Q4 		$5.11M Sell
45,560
-776
-2% -$77.6K ﹤0.01% 2928
2015
Q3 		$4.46M Buy
46,336
+37,170
+406% +$4.26M ﹤0.01% 2996
2015
Q2 		$939K Buy
9,166
+8,385
+1,074% +$651K ﹤0.01% 4171
2015
Q1 		$48K Sell
781
-2,046
-72% -$114K ﹤0.01% 5677
2014
Q4 		$124K Buy
2,827
+2,150
+318% +$98.5K ﹤0.01% 5734
2014
Q3 		$38K Sell
677
-8,139
-92% -$410K ﹤0.01% 6688
2014
Q2 		$396K Buy
8,816
+8,216
+1,369% +$338K ﹤0.01% 4855
2014
Q1 		$29K Buy
+600
New +$30.9K ﹤0.01% 6726

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of America's RARE Position: Q1 2026 in Review

Bank of America reduced its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, selling an estimated $3.77M and leaving 1,046,546 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Bank of America first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $51.4M in Q3 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Bank of America held 1,046,546 shares of Ultragenyx Pharmaceutical worth $21.9M as of Q1 2026.
  • Bank of America sold 167,382 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.77M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2305 holding.
  • Bank of America first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Bank of America's Ultragenyx Pharmaceutical position peaked at $51.4M in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.